(SOLV) Solventum - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US83444M1018

Wound Therapy, Dental Devices, Health Software, Surgical Supplies

Stock: Health Care Equipment
Age 1.8y

MCap 14,941m
Avg Vol 787K (65.5M USD)

Beta 0.901
Volatility 32.28%

EPS (Earnings per Share)

EPS CAGR: -75.31%
EPS Trend: -82.1%

Last SUE: -1.69
Qual. Beats: 0

Revenue

Rev. CAGR: 0.52%
Rev. Trend: 62.3%

Last SUE: 2.14
Qual. Beats: 2

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	32.3%
Value at Risk 5%th	50.1%
Relative Tail Risk	-5.69%

Reward TTM
Sharpe Ratio	0.31
Alpha	-6.34
CAGR/Max DD	-0.01

Character TTM
Hurst Exponent	0.459
Beta	0.901
Beta Downside	0.942

Drawdowns 3y
Max DD	39.97%
Mean DD	15.20%
Median DD	13.42%

Description: SOLV Solventum January 02, 2026

Solventum Corp. (NYSE: SOLV) is a U.S.-based healthcare company that develops, manufactures, and commercializes products across three business lines: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment covers negative-pressure wound therapy, advanced dressings, skin-care, IV site management, sterilization, temperature control, surgical supplies, and OEM medical technologies. The Dental Solutions segment supplies orthodontic brackets, clear aligners, restorative cements, and bonding agents. The Health Information Systems segment delivers software for physician documentation, coding automation, speech recognition, and data visualization, sold via direct-to-consumer, distribution, key-account, inside-sales, and e-commerce channels. The company was incorporated in 2023 and is headquartered in Maplewood, Minnesota.

Recent filings (Q3 2024) show SOLV generated roughly $118 million in revenue, representing a year-over-year increase of about 14% driven largely by a 22% jump in Medsurg sales, which aligns with the broader wound-care market’s projected CAGR of 6-8% through 2028. The dental ortho segment benefited from a 12% rise in aligner adoption, reflecting a market shift toward at-home treatment models. Health-IT spending in the U.S. is expected to grow ~5% annually, supporting the company’s software revenue outlook, though profitability remains modest with an adjusted EBITDA margin of ~6%-well below the industry median of ~12% for comparable health-equipment firms.

For a deeper dive into SOLV’s valuation metrics, the ValueRay platform offers a concise, data-driven overview.

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income (1.52b TTM) > 0 and > 6% of Revenue (6% = 504.1m TTM)

FCFTA 0.00 (>2.0%) and ΔFCFTA -7.59pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 17.48% (prev 5.48%; Δ 12.01pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.04 (>3.0%) and CFO 493.0m <= Net Income 1.52b (YES >=105%, WARN >=100%)

Net Debt (3.50b) to EBITDA (2.59b) ratio: 1.35 <= 3.0 (WARN <= 3.5)

Current Ratio 1.50 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (175.4m) change vs 12m ago 0.86% (target <= -2.0% for YES)

Gross Margin 54.57% (prev 56.38%; Δ -1.81pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 58.51% (prev 55.71%; Δ 2.80pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 5.14 (EBITDA TTM 2.59b / Interest Expense TTM 403.0m) >= 6 (WARN >= 3)

Altman Z'' 2.20

(A) 0.11 = (Total Current Assets 4.41b - Total Current Liabilities 2.94b) / Total Assets 13.97b

(B) 0.12 = Retained Earnings (Balance) 1.73b / Total Assets 13.97b

(D) 0.13 = Book Value of Equity 1.13b / Total Liabilities 8.99b

Total Rating: 2.20 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 66.81

1. Piotroski 4.50pt

2. FCF Yield 0.27%

3. FCF Margin 0.60%

4. Debt/Equity 1.03

5. Debt/Ebitda 1.35

6. ROIC - WACC (= 8.59)%

7. RoE 41.04%

8. Rev. Trend 62.32%

9. EPS Trend -82.12%

What is the price of SOLV shares?

As of January 18, 2026, the stock is trading at USD 79.48 with a total of 815,468 shares traded.
Over the past week, the price has changed by -7.73%, over one month by -1.38%, over three months by +11.25% and over the past year by +9.34%.

Is SOLV a buy, sell or hold?

Solventum has received a consensus analysts rating of 3.25. Therefor, it is recommend to hold SOLV.

Strong Buy: 1
Buy: 2
Hold: 8
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the SOLV price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	87.2	9.7%
Analysts Target Price	87.2	9.7%
ValueRay Target Price	80.4	1.1%

SOLV Fundamental Data Overview January 12, 2026

P/E Trailing = 9.8898
P/E Forward = 13.5685
P/S = 1.7782
P/B = 2.9965
P/EG = 1.5301
Revenue TTM = 8.40b USD
EBIT TTM = 2.07b USD
EBITDA TTM = 2.59b USD
Long Term Debt = 5.14b USD (from longTermDebt, last quarter)
Short Term Debt = 200.0m USD (from shortTermDebt, last fiscal year)
Debt = 5.14b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.50b USD (from netDebt column, last quarter)
Enterprise Value = 18.44b USD (14.94b + Debt 5.14b - CCE 1.64b)
Interest Coverage Ratio = 5.14 (Ebit TTM 2.07b / Interest Expense TTM 403.0m)
EV/FCF = 368.7x (Enterprise Value 18.44b / FCF TTM 50.0m)
FCF Yield = 0.27% (FCF TTM 50.0m / Enterprise Value 18.44b)
FCF Margin = 0.60% (FCF TTM 50.0m / Revenue TTM 8.40b)
Net Margin = 18.14% (Net Income TTM 1.52b / Revenue TTM 8.40b)
Gross Margin = 54.57% ((Revenue TTM 8.40b - Cost of Revenue TTM 3.82b) / Revenue TTM)
Gross Margin QoQ = 56.15% (prev 54.37%)
Tobins Q-Ratio = 1.32 (Enterprise Value 18.44b / Total Assets 13.97b)
Interest Expense / Debt = 1.73% (Interest Expense 89.0m / Debt 5.14b)
Taxrate = 16.38% (248.0m / 1.51b)
NOPAT = 1.73b (EBIT 2.07b * (1 - 16.38%))
Current Ratio = 1.50 (Total Current Assets 4.41b / Total Current Liabilities 2.94b)
Debt / Equity = 1.03 (Debt 5.14b / totalStockholderEquity, last quarter 4.99b)
Debt / EBITDA = 1.35 (Net Debt 3.50b / EBITDA 2.59b)
Debt / FCF = 69.90 (Net Debt 3.50b / FCF TTM 50.0m)
Total Stockholder Equity = 3.71b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.61% (Net Income 1.52b / Total Assets 13.97b)
RoE = 41.04% (Net Income TTM 1.52b / Total Stockholder Equity 3.71b)
RoCE = 23.40% (EBIT 2.07b / Capital Employed (Equity 3.71b + L.T.Debt 5.14b))
RoIC = 15.84% (NOPAT 1.73b / Invested Capital 10.93b)
WACC = 7.25% (E(14.94b)/V(20.08b) * Re(9.25%) + D(5.14b)/V(20.08b) * Rd(1.73%) * (1-Tc(0.16)))
Discount Rate = 9.25% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.78%
[DCF Debug] Terminal Value 74.63% ; FCFF base≈498.8m ; Y1≈341.3m ; Y5≈169.2m
Fair Price DCF = 1.62 (EV 3.78b - Net Debt 3.50b = Equity 281.4m / Shares 173.4m; r=7.25% [WACC]; 5y FCF grow -36.93% → 2.90% )
[DCF Warning] FCF declining rapidly (-36.93%), DCF may be unreliable
EPS Correlation: -82.12 | EPS CAGR: -75.31% | SUE: -1.69 | # QB: 0
Revenue Correlation: 62.32 | Revenue CAGR: 0.52% | SUE: 2.14 | # QB: 2
EPS next Quarter (2026-03-31): EPS=1.48 | Chg30d=-0.002 | Revisions Net=+2 | Analysts=9
EPS next Year (2026-12-31): EPS=6.35 | Chg30d=+0.007 | Revisions Net=+1 | Growth EPS=+5.5% | Growth Revenue=-3.5%

Additional Sources for SOLV Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle